Furthermore, high HER2 expression predicted an unfavorable oncologic outcome, and low CAIX and high ERCC1 expression predicted an unfavorable response to adjuvant treatment in patients with early cervical cancer. Here, ERBB2 is linked to cervical carcinoma.